HELIOS- A:A Study to Evaluate the Efficacy and | Clinical Research Studies Listing

HELIOS- A:A Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients with Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)

Recruiting

18 years - 85 years

All

Phase 3

164 participants needed

1 Location

Brief description of study

The purpose of this study is to evaluate the efficacy and safety of vutrisiran (ALN-TTRSC02) in patients with hereditary transthyretin amyloidosis (hATTR amyloidosis). Participants will receive vutrisiran or the reference comparator patisiran during the Treatment Period.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Hereditary Transthyretin Amyloidosis,hATTR Amyloidosis
Age: 18 years - 85 years
Gender: All

Male or female ; 18 to 85 years of age ; Has a diagnosis of hATTR amyloidosis with transthyretin (TTR) mutation;

Updated on 04 Aug 2024. Study ID: 832041

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

HELIOS- A:A Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients with Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)

Brief description of study

Eligibility of study

Find a site

Interested in the study